NYSE:PFEPharmaceuticals
Should FDA Approval of Updated COVID Vaccine for Vulnerable Groups Prompt a Closer Look at Pfizer (PFE)?
On August 27, 2025, BioNTech SE and Pfizer Inc. announced that the U.S. FDA approved their supplemental Biologics License Application for the LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY LP.8.1 COVID-19 Vaccine, mRNA), authorizing its use for adults 65 and older and high-risk individuals ages 5 to 64.
This approval expands access to updated COVID-19 protection for vulnerable populations, highlighting the ongoing importance of vaccine adaptation in public health efforts.
We'll...